Terms: = Colorectal cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Clinical Outcome
3 results:
1. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer.
Li J; Huang J; Huang F; Jin Q; Zhu H; Wang X; Chen M
Oncotarget; 2016 Nov; 7(45):73638-73650. PubMed ID: 27655638
[TBL] [Abstract] [Full Text] [Related]
2. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract] [Full Text] [Related]
3. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B
J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066
[TBL] [Abstract] [Full Text] [Related]
